This is a test where a small sample of blood is taken to look for cancer cells or clues about cancer. It's called 'liquid' because it's done using a blood sample, not a needle biopsy. It helps doctors find cancer early or check if treatment is working.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
A liquid biopsy is a laboratory test, usually done on an ordinary blood sample, that looks for traces of cancer: cancer cells, or fragments of DNA and other molecules that tumors shed into the bloodstream. Doctors often call this material circulating tumor DNA (ctDNA). Because it needs only a blood draw rather than a needle or surgical sample from the tumor itself, it can be repeated over time. The name covers several quite different tests, and which one is being offered matters more than the label. The most established use is for people already diagnosed with cancer, especially advanced cancer. Here the test reads the tumor's genetic changes to look for one that a targeted medicine is designed to act on. It is particularly useful when a tumor is hard to reach with a needle, when a tissue sample is too small to test, or when faster results would change treatment. Guardant360 CDx and FoundationOne Liquid CDx are tests of this kind approved by the US Food and Drug Administration (FDA). Even so, a tissue biopsy remains the preferred test for many cancers, because blood tests can miss some types of genetic change. A second use is screening people without symptoms. Shield, approved by the FDA in 2024, is a blood test for colorectal cancer screening in adults at average risk, starting at age 45. Multi-cancer detection tests, which look for signals of many cancers at once, are offered by some companies but are still being studied, and it is not yet known whether they help people live longer. A third use, still developing, is checking for traces of cancer after treatment to estimate the chance it will come back.
For most liquid biopsies there is no special preparation: no fasting and no need to change your usual medicines, unless the ordering clinician says otherwise. The more important preparation is understanding which test is being ordered and what question it is meant to answer, whether that is choosing treatment, screening or monitoring. It is worth asking about cost before the sample is drawn. Coverage depends on the test, the type of cancer and the insurance plan. Insurers often pay for genomic testing that guides cancer treatment when the evidence supports it, but they typically do not pay for multi-cancer screening tests. Some genomic tests can also reveal a gene change you may have been born with, which could matter for relatives, so it helps to decide in advance how you would want that kind of finding handled.
The procedure itself is a routine blood draw. A health care worker places a needle in a vein, usually in the arm, and fills one or more tubes, which takes a few minutes. You may feel a brief sting or pinch. No sedation or anesthesia is involved, and some tests use a different fluid, such as urine. The real work happens in the laboratory. Tumor DNA usually makes up only a tiny fraction of the DNA in blood, so the lab uses sensitive sequencing methods to find and read it. The tubes need careful handling and timely shipping, which is one reason these tests are usually sent to specialized laboratories.
There is no recovery period. Slight soreness or a small bruise where the needle went in is common and usually fades quickly, and you can go straight back to normal activities. Results commonly take about a week or longer, depending on the test and the laboratory. The report goes to the ordering clinician, who explains what it means for you. For someone with cancer, a finding that matches a targeted treatment may change the treatment plan. If no tumor DNA or no relevant change is found, that does not prove there is none: the tumor may simply not have shed enough DNA into the blood, and a tissue biopsy may be recommended to check. A positive screening result is a signal, not a diagnosis. After a positive Shield test, a colonoscopy is needed to find out what is there, and skipping that step defeats the purpose of screening. A positive multi-cancer test likewise leads to further scans or procedures to look for a cancer.
The blood draw itself carries very little physical risk beyond brief discomfort or bruising. The meaningful risks come from how the results are read and what happens next. False negatives are the main limitation. Cancers do not all release enough DNA to detect, and blood tests are weaker than tissue tests at finding some kinds of genetic change, so a clear result can be falsely reassuring. For colorectal screening, Shield found about 83 percent of the cancers that colonoscopy found, but only about 13 percent of advanced precancerous polyps. That matters because colonoscopy can remove those polyps and prevent cancer, so a blood test is not equivalent. False or misleading positives also occur. With age, blood-forming cells can pick up their own harmless-seeming mutations (a process called clonal hematopoiesis), and these can be mistaken for tumor changes, which could point toward the wrong treatment. In screening, a positive result that turns out not to be cancer can lead to more tests, each with its own risks, plus anxiety and cost. A test may also reveal an inherited gene change, which usually needs a separate confirmatory genetic test.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Liquid Biopsy, what to expect, or ask the community a question.